Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
David Lebowitz, an analyst from Citi, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The associated price target ...
Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...
1d
On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price raised by Scotiabank from $45.00 to $48.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector ...
GlobalData on MSN1d
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...
Zacks.com on MSN1h
BridgeBio Stock Up on FDA Approval of Cardiovascular DrugBridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback